Mizuho Forecasts Strong Price Appreciation for Quest Diagnostics (NYSE:DGX) Stock

Quest Diagnostics (NYSE:DGX) had its target price increased by investment analysts at Mizuho from $235.00 to $260.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Mizuho’s target price suggests a potential upside of 14.01% from the company’s current price.

A number of other brokerages have also issued reports on DGX. UBS Group reaffirmed a “neutral” rating and set a $232.00 target price on shares of Quest Diagnostics in a research report on Friday. Robert W. Baird increased their price target on shares of Quest Diagnostics from $236.00 to $255.00 and gave the company a “neutral” rating in a report on Friday. Wall Street Zen downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Weiss Ratings upgraded shares of Quest Diagnostics from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, July 9th. Finally, Evercore set a $225.00 price objective on shares of Quest Diagnostics in a report on Tuesday, April 21st. Six analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $231.73.

Quest Diagnostics Stock Performance

DGX opened at $228.05 on Friday. The firm has a market capitalization of $25.25 billion, a P/E ratio of 24.21, a price-to-earnings-growth ratio of 2.61 and a beta of 0.58. The stock’s 50 day moving average price is $203.23 and its two-hundred day moving average price is $197.59. The company has a quick ratio of 1.08, a current ratio of 1.59 and a debt-to-equity ratio of 0.72. Quest Diagnostics has a 12-month low of $165.78 and a 12-month high of $237.78.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.82 by $0.30. Quest Diagnostics had a return on equity of 16.01% and a net margin of 9.18%.The company had revenue of $3.04 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same period in the previous year, the business posted $2.62 EPS. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. Quest Diagnostics has set its FY 2026 guidance at 11.050-11.250 EPS. On average, equities analysts forecast that Quest Diagnostics will post 11.17 earnings per share for the current year.

Insiders Place Their Bets

In related news, SVP Karthik Kuppusamy sold 8,147 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the transaction, the senior vice president directly owned 13,510 shares of the company’s stock, valued at $2,702,000. This trade represents a 37.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the completion of the transaction, the chief executive officer directly owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This trade represents a 7.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.88% of the company’s stock.

Hedge Funds Weigh In On Quest Diagnostics

A number of hedge funds and other institutional investors have recently made changes to their positions in DGX. Norges Bank acquired a new position in Quest Diagnostics in the fourth quarter worth about $229,522,000. Boston Partners grew its stake in shares of Quest Diagnostics by 32.8% in the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock valued at $767,978,000 after purchasing an additional 997,033 shares during the period. EdgePoint Investment Group Inc. grew its stake in shares of Quest Diagnostics by 95.5% in the 4th quarter. EdgePoint Investment Group Inc. now owns 1,661,072 shares of the medical research company’s stock valued at $288,246,000 after purchasing an additional 811,320 shares during the period. UBS Group AG grew its stake in shares of Quest Diagnostics by 67.8% in the 4th quarter. UBS Group AG now owns 1,114,451 shares of the medical research company’s stock valued at $193,391,000 after purchasing an additional 450,161 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of Quest Diagnostics by 36.3% in the 2nd quarter. Bank of America Corp DE now owns 1,599,602 shares of the medical research company’s stock worth $287,337,000 after buying an additional 426,399 shares in the last quarter. 88.06% of the stock is owned by institutional investors.

Quest Diagnostics News Roundup

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Quest Diagnostics posted Q2 results that beat Wall Street expectations on both revenue and earnings, helped by stronger demand for routine diagnostic and preventive testing. The company also raised its full-year 2026 outlook, which investors are reading as evidence that growth is holding up well. Article: Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
• Positive Sentiment: Mizuho raised its price target on DGX to $260 and kept an outperform rating, signaling confidence that the company can still outperform from here. Article: Quest Diagnostics price target raised by Mizuho
• Positive Sentiment: Truist also lifted its target to $250, while Robert W. Baird increased its target to $255, reflecting continued analyst optimism after the earnings beat and raised guidance. Article: Quest Diagnostics price target raised by Truist Financial Corporation
• Neutral Sentiment: Several market commentary pieces highlighted DGX as a momentum stock and noted the shares recently reached a 52-week high. That supports bullish sentiment, but these articles are mostly follow-up coverage rather than a new fundamental catalyst. Article: Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) Is a Great Choice

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.